Analysis focus: GALT
Galectic (GALT) was our focus ticker in one of the articles in the NASH series we did in February. There, we discussed what makes Galectin stand out among the NASH companies. First, it is not a one-trick pony and has a diverse pipeline outside NASH. Second, unlike Genfit and Intercept, it targets a more difficult area of NASH, namely cirrhosis and fibrosis, and therefore the bets are very high here.
Here’s what we wrote: “With GR-MD-02, Galectin is also targeting a different spectrum of NASH. The company’s programs with GR-MD-02 are focusing